We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
Thanks to our healthcare, teaching and research potential, we work to incorporate new knowledge to generate value for patients, professionals and the organization itself.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Hospital donations
Research donations
Dr. Moein Moghimi -Professor of Pharmaceutics and Nanomedicine- School of Pharmacy, Newcastle University, Division of Stratified Medicine, Biomarkers and Therapeutics, Institute of Cellular Medicine, Newcastle
"Of pigs and men: the illusive story of infusion-reactions to nanoparticulate medicines"
Adverse infusion reactions to regulatory approved nanopharmaceuticals in human subjects are idiosyncratic, but outwardly reproducible in pigs. Equivocal investigations also indict a role for the complement system in adverse reactions to nanopharmaceuticals, where the extent of nanomedicine-mediated complement activation in human serum is curiously correlated to cardiopulmonary responses in pigs. Contrary to these beliefs, a large body of evidence from this and other laboratories suggest that the porcine reactions are related to robust nanoparticle clearance by pulmonary intravascular macrophages (PIMs) irrespective of complement activation, and rapid release of arachidonate metabolites from these cells. Similar to pigs, other animals that have resident PIMs in their lungs also respond to intravenously injected particles, where rapid particle clearance by PIMs correlate with peak periods of cardiopulmonary distress. Normal human lungs, however, do not have PIMs, but “induced” PIMs have been identified in pulmonary circulation dependent on pathological conditions. Apparently, nanomedicine-mediated infusion reactions in humans are related to a moment of macrophage intoxication by induced PIMs and/or other macrophages outside the pulmonary circulation, but avoidable with appropriate dosing or through simple nanoengineering strategies. Notwithstanding, global nanomedicine safety assessment in the porcine model (and other ruminants and species with PIMs) is inappropriate and misleading, and these models should not be advertently promoted and their applications exaggerated
Host: CIBBIM-Nanomedicina. Direccionament i Alliberament Farmacològic simo.schwartz@vhir.org
cartell_de_la_conferencia.pdf
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights". Operated by: Vall d’Hebron University Hospital Foundation – Research Institute. Purpose: Manage the user’s contact information. Legitimisation: Express acceptance of the privacy policy. Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use. Source: The interested party themselves.